Pfizer Vulnerable to Threat of European Tariffs, CEO Says
Pfizer Inc. is vulnerable to the possibility that President Donald Trump will place tariffs on the European Union, where the ...
Moderna, Inc.: Working Hard But Competition Is Working Harder
MRNA's competitive landscape, particularly against Pfizer, and higher forward P/S ratio suggest the stock is overvalued and ...
Global Influenza Vaccine Market is Projected to Cross USD 14 Billion Mark by 2032 | DelveInsight
DelveInsight's Influenza Vaccine Market Insights report provides the current and forecast market analysis, individual leading ...
Pfizer stops commercialization of hemophilia gene therapy Beqvez
Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing ...
Is Pfizer Inc. (PFE) the Best Drug Stock to Buy Now?
Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...
Dividend Harvesting Portfolio Week 207: $20,700 Allocated, $2,010.09 In Projected Dividends
Discover investment insights as the S&P 500 climbs 3.96% YTD. Learn about dividend-focused strategies and stock picks for ...
Harvard Medical School11h
Scientists Identify New Driver of Inflammation Implicated in Autoimmune Diseases
Researchers identify a new player in human immunity that can go rogue and turn the immune system against the body’s own ...
BizWest1d
Ambrosia adds ex-ArcherDX, Array exec to board
Ambrosia Biosciences Inc., a drug-discovery company launched last year, has added Jason Haddock, a former executive with ArcherDX Inc. and Array BioPharma Inc., to its board of directors.